This page is intended for healthcare professionals only.
Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a life-threatening malignancy that presents challenges in the management of transplant patients.
See how other clinicians answered.
At what point in the patient’s journey do you take action to treat suspected EBV+PTLD?
Which type of EBV+PTLD patients do you most commonly treat?
Understanding the risk factors associated with EBV+ PTLD may help your diagnosis.
Get the latest information about EBV+ PTLD in your inbox.
You are now leaving EBVPTLD.com
Please be aware that the sponsors of this site are not responsible for and do not manage the accuracy, content, practices, or standards on the site you are about to enter.
For direct or time-sensitive inquiries about EBV+ PTLD, please contact Atara at:
MedInfo@atarabio.com for Medical Information
Disclaimer Atara Biotherapeutics will not send any patient or treatment-related information.
Atara Biotherapeutics, Inc.
611 Gateway Blvd, Suite 900
South San Francisco, CA 94080
+1 (650) 278-8930
Atara Biotherapeutics Switzerland GmbH
6300 Zug, Switzerland
+41 41 561 3250
Copyright © 2019 Atara Biotherapeutics. All Rights Reserved. US -1800006 12/2019